Core Viewpoint - The company has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1] Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1] - Cimetidine Injection is indicated for the treatment of gastrointestinal ulcers, expanding the company's product pipeline and categories [1] - This approval is expected to strengthen the company's position in the chronic disease medication market [1]

Core Viewpoint - The company Yipinhong (300723.SZ) has received the drug registration certificate for Cimetidine Injection from the National Medical Products Administration, allowing it to sell this product in the domestic market, which enhances its competitiveness in the chronic disease medication sector [1]. Group 1 - The company's wholly-owned subsidiary, Guangzhou Lianrui Pharmaceutical Co., Ltd., has obtained the registration certificate for Cimetidine Injection, indicating its eligibility to market this drug in China [1]. - The indication for Cimetidine Injection is for the treatment of gastrointestinal ulcers, which expands the company's product offerings [1]. - This approval will further enrich the company's product pipeline and categories, strengthening its position in the chronic disease medication field [1].